Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias - Wikidata - wikimedia - TriplyDB

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

http://www.wikidata.org/entity/Q57750814

about

The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis Emerging candidate biomarkers for Parkinson's disease: a review More than a Rumor Spreads in Parkinson's Disease Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia The role of biomarkers and imaging in Parkinson's disease.Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data.Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease.Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review.Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.Interaction between pathogenic proteins in neurodegenerative disorders.Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.Biomarkers for trials of neuroprotection in Parkinson's disease.Neurobiology of cognitive impairment in Parkinson's disease.Cerebrospinal fluid biomarkers in Parkinson disease.Ascertainment bias in dementias: a secondary to tertiary centre analysis in Central Italy and conceptual review.Recent developments in biomarkers in Parkinson disease Molecular biomarkers of neurodegeneration.Biomarker time out.Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update.Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.How many biomarkers to discriminate neurodegenerative dementia?

P2860

Q26785974-481E4F9D-045F-49E0-BACE-C1B2A601CC57 Q27015018-86B91D7C-0BC9-47E1-9286-7DD1AF70DC8D Q28066571-F626707B-4F90-4C2C-9721-C03A5C7369CB Q28082380-567FF385-9B73-4BCF-B46A-C52424A0FF9B Q28545821-E7387604-F556-495F-B07C-7D440CB59F5B Q28552902-172D77D4-B15D-42EF-B571-3009A650F56F Q31041660-F84C495A-72F8-45AF-9D6D-2F012B1B8074 Q31096478-45D8428D-A50A-4D56-A362-A450E7066FFF Q34118169-05F9B9F3-F368-4FC9-88CE-7AE35A2843DA Q34237637-1A7D1E35-8A07-45A1-9350-187D38AF06FD Q34356116-65557C4E-78FF-414F-9D1D-16A010979BB7 Q34544824-956043E2-2561-424C-B4AD-5EB7BB0E3276 Q34714560-E2582BA1-B61D-4E4F-B1C7-389551E17865 Q34806122-3DD91B6C-724A-4BE2-8796-6C66F1AB13A9 Q35055373-A75EB5E1-62CC-4D66-AF61-730E82DD8F8A Q35139572-A55820C4-CDE4-4AE0-A56C-8EC84E6C3DD8 Q35597118-70DC7E39-2DAB-46D9-8BA2-9109174E2C07 Q35897340-4A60F616-EE8F-4A5B-8CAC-D75175565FAD Q35969183-54CEA63F-95B9-4CDA-A7A4-2B83BF7A2DE8 Q36120659-CA909DDC-B739-479D-AA31-4314B46EA6A8 Q36245278-5A30ADE2-66CE-4C73-8A14-275E5A029932 Q36551527-20A9E9FD-86F9-4F12-ACA8-CCB4895F69A1 Q37225128-18B9E62E-AE20-4BF4-A045-2DFB724075C1 Q37272860-54333E1C-45EF-4C9B-AB94-5850B17B83FB Q37345484-2F8F1819-927A-40C4-B41E-ED9C016E70F7 Q37969262-2FF23582-5419-423B-A544-36563018C0CF Q38037155-40CE559E-822E-4038-BED6-7585259BC18D Q38038544-381EDD04-B501-44F1-A0D2-DDA4BCF2DC7E Q38067143-6FCB1B28-1DFC-4CE1-9DE6-488B490DBC0D Q38082586-E5B8DED1-54AB-436C-90FB-CEA45B84F27E Q38115735-268D6DA8-F152-42C6-872E-C65B48EE8948 Q38119095-66FA40EA-6A0B-4167-9C72-84137D393D95 Q38154930-4FF7922C-1EE1-4C97-B727-09132CCC8D0C Q38190038-AAAB08A3-74DC-4759-8A83-AC97DC0CC51F Q38247307-48B6B87A-F1A3-4816-AD5B-BBF882954C4E Q38271572-8CA5800D-2E44-489D-B006-D3E0F1286037 Q38289739-068FE32B-F769-40B3-B785-4BBA1EB5E173 Q38392505-655272EF-C315-4EA4-8179-FE664E076E28 Q38421118-535F5093-59A2-4D95-9EAB-1D1B990EB110 Q38570242-4B26AA58-7FBF-4ECC-9CF0-2429686453EF

P2860

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

http://www.wikidata.org/entity/Q57750814

description

im April 2011 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 05 April 2011

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у квітні 2011

@uk

name

Cerebrospinal fluid Tau/α-synu ...... ase and degenerative dementias

@en

Cerebrospinal fluid Tau/α-synu ...... ase and degenerative dementias

@nl

type

label

Cerebrospinal fluid Tau/α-synu ...... ase and degenerative dementias

@en

Cerebrospinal fluid Tau/α-synu ...... ase and degenerative dementias

@nl

prefLabel

Cerebrospinal fluid Tau/α-synu ...... ase and degenerative dementias

@en

Cerebrospinal fluid Tau/α-synu ...... ase and degenerative dementias

@nl

P1433

Q57750814-A8429C9D-82DD-480A-86E7-1B4B9A49C6FB

P1476

Q57750814-3187CD12-F88A-478E-9732-DC449D27E287

P2093

Q57750814-04BBAF12-AE57-4F85-91C8-58B8CD6C4DDF

Q57750814-07FF6AD1-E2DF-4891-835B-045DBDB17B2B

Q57750814-240DC3E4-93F9-4717-B38D-D0125BEAD53F

Q57750814-415E5D55-4540-4E91-931D-B4FE6E7427F3

Q57750814-65D75BF0-2626-4309-BB25-01D46022E6A6

Q57750814-6753128E-8217-4E98-B8C8-55884A9BC838

Q57750814-6BEF039F-A898-4DA1-AEED-E89092D13C29

Q57750814-88B678AD-4FE4-4622-97BB-93EDF01B67D3

Q57750814-9E7C4445-EA45-4B15-89CC-A6C255AD13B1

Q57750814-C5148659-10F0-4559-82F1-F963AE178177

P2860

Q57750814-0218C5A5-82F6-4339-AB9A-557E4956341F

Q57750814-0320735F-C08D-4F92-BCAA-3356FBA62D36

Q57750814-0554A554-E254-4669-94A3-8D5DE3D12997

Q57750814-1AB58C55-217B-4675-8830-D8C95D843A68

Q57750814-2866DF03-C2DA-4065-B887-0F96CF8552FE

Q57750814-2957FB98-E165-4A32-8E20-4E100D187402

Q57750814-297C1787-6F66-44FA-A127-F9C7584F8BED

Q57750814-35E243BF-3490-4C19-97C5-9004F374A944

Q57750814-371BE8D5-89E8-4A91-908B-285D88120153

Q57750814-47FCC19E-74C5-4C74-A9A5-01DA1AB58034

P304

Q57750814-45CE12EB-4DDE-45C6-AC78-D97A660741AC

P31

Q57750814-2A91A9DC-8886-47D6-8464-CDF6BF4B1CF1

P356

Q57750814-40EBE97A-6139-43F0-88EA-B37F5EF41CC0

P407

Q57750814-85330ECC-494D-44DF-9DFD-8EB4F71F8118

P433

Q57750814-9A6374DC-E98C-4A5C-B4BF-3830A79C0B3E

P478

Q57750814-009DBFF6-8AE1-448E-9A82-8C28DF6D3299

P50

Q57750814-132E3A07-E4A0-4D91-9A71-504536AAA129

Q57750814-3BE7C34F-8277-4A86-8584-DD636D7C0995

Q57750814-99ACB1B8-757B-4419-B722-479063C026E3

Q57750814-B094FB87-02B7-4A04-B560-F7A9468807AE

P577

Q57750814-CD6A4C9C-484D-4CB5-AEE8-F38FBCEAB809

P698

Q57750814-8E6FDCA6-F5E1-49A3-B4CC-0416004DD56E

P921

Q57750814-71CD62AA-A6D3-4F4A-8370-C4982CD1D100

Q57750814-BFEA6280-5016-4AB4-A791-C259328B4755

Q57750814-D09D631F-DC6A-4F1B-BB4C-8061AEF76CA1

P356

P1433

Movement Disorders

P1476

Cerebrospinal fluid Tau/α-synu ...... ase and degenerative dementias

@en

P2093

Alessandro Padovani

http://www.w3.org/2001/XMLSchema#string

Aroldo Rossi

http://www.w3.org/2001/XMLSchema#string

Barbara Borroni

http://www.w3.org/2001/XMLSchema#string

Claudia De Carlo

http://www.w3.org/2001/XMLSchema#string

Davide Chiasserini

http://www.w3.org/2001/XMLSchema#string

Gianni Bellomo

http://www.w3.org/2001/XMLSchema#string

Lucilla Parnetti

http://www.w3.org/2001/XMLSchema#string

Mohamed M Qureshi

http://www.w3.org/2001/XMLSchema#string

Mustafa T Ardah

http://www.w3.org/2001/XMLSchema#string

Nicola Tambasco

http://www.w3.org/2001/XMLSchema#string

P2860

Alpha-synuclein in Lewy bodies

Genes associated with Parkinson syndrome.

Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment.

Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia.

Interactions of amyloidogenic proteins.

Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications.

Synapse loss in dementias.

CSF markers for incipient Alzheimer's disease.

P304

1428-1435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.23670

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

David Giannandrea

P577

2011-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21469206

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease